Phio Pharmaceuticals Corp. is a biotechnology company, which engages in the development of immuno-oncology therapeutics that address unmet medical needs. Its clinical product candidate includes RXI-109, a RNAi compound developed for the reduction of dermal scarring in planned surgeries. The company was founded on September 8, 2011 and is headquartered in Marlborough, MA.
⭐⭐⭐ Sign Up for Free ⭐⭐⭐
1) Download our Mobile App >> link-to.app/dexwirenews
2) Join our Telegram >> t.me/DEXWireNews
3) Join us on WhatsApp >> dexwirenews.com/WhatsApp
4) Follow @DEXWireNews on Social Media
1) Download our Mobile App >> link-to.app/dexwirenews
2) Join our Telegram >> t.me/DEXWireNews
3) Join us on WhatsApp >> dexwirenews.com/WhatsApp
4) Follow @DEXWireNews on Social Media